Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Novel heterocyclic compounds and pharmaceutical composition containing them|
|Abstract:||The invention relates to the production of compounds of the general formula: ##STR1## wherein X is selected from the group consisting of oxygen, CH.sub.2 and CH radicals, and when X designates oxygen, R designates alkyl, isoalkyl, aralkyl, and substituted aralkyl groups and when X designates CH.sub.2 then R designates alkyl, phenyl or substituted phenyl group, and A-B is a single bond, and when X designates CH.sub.2, R designates alkyl, phenyl or substituted phenyl groups and A-B is a double bond; and physiologically acceptable salts of these, and pharmaceutical compositions containing the same as active ingredient.|
|Inventor(s):||Cohen; Sasson (Tel-Aviv, IL), Fisher; Abraham (Holon, IL)|
|Assignee:||The Purdue Frederick Company (Norwalk, CT)|
|Filing Date:||Oct 23, 1978|
|Claims:||1. A process for the production of a salt of a compound of the formula: ##STR8## wherein X is oxygen, and wherein R is a radical selected from the group consisting of lower alkyl, cyclopentyl and cyclohexyl, which comprises reacting 2-methylenequinuclidin-3-one with the corresponding radical -substituted diloweralkylmalonate in the presence of sodium alkoxide to give the corresponding 3-oxoquinuclidin-2-yl) malonate, reducing the latter with sodium borohydride to the corresponding (3-hydroxyquinuclidin-2-yl malonate, and treating the latter with a concentrated mineral acid to obtain the desired product, a 4-radical-6-oxa-1-azatricyclo (126.96.36.199.sup.2,7) dodecan-5-one salt. |
2. A process for the production of a salt of a compound of the formula: ##STR9## wherein X is oxygen and R is a radical selected from the group consisting of thienyl, phenyl, methylphenyl, methoxyphenyl, chlorophenyl, trifluromethylphenyl, aminophenyl, di-loweralkylaminophenyl and benzyl, which comprises reacting 2-methylene quinuclidin-3-one with the corresponding radical-substituted diloweralkylacetate in the presence of sodium alkoxide to give the corresponding (3-oxoquinuclidin-2-yl) acetate, reducing the latter with sodium borohydride to the corresponding (3-hydroxyquinuclidin-2-yl) acetate, and treating the latter with a concentrated mineral acid to obtain the desired product, a 4-radical-6-oxa-1-azatricyclo(188.8.131.52.sup.2.7) dodecan-5-one salt.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.